Two Sigma Advisers
NVNO

Two Sigma Advisers’s enVVeno Medical NVNO Stock Holding History

Two Sigma Advisers’s Portfolio NVNO Stock Details NVNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-400
Closed -$4.49K – 1450
2025
Q4 		$4.49K Buy
+400
New +$7.77K ﹤0.01% 2329
2023
Q1 		– Sell
-380
Closed -$67.8K – 2706
2022
Q4 		$67.8K Sell
380
-120
-24% -$24.4K ﹤0.01% 2337
2022
Q3 		$110K Sell
500
-557
-53% -$119K ﹤0.01% 2297
2022
Q2 		$140K Sell
1,057
-360
-25% -$55.9K ﹤0.01% 2345
2022
Q1 		$316K Sell
1,417
-894
-39% -$173K ﹤0.01% 2198
2021
Q4 		$533K Buy
+2,311
New +$651K ﹤0.01% 1885

Other funds holding NVNO

KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WIM
Westside Investment Management Santa Monica, California $653M AUM 28.36% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Two Sigma Advisers's NVNO Position: Q1 2026 in Review

Two Sigma Advisers sold out of enVVeno Medical (NVNO) in Q1 2026, closing a stake of 400 shares — an estimated $4.49K sold.

Two Sigma Advisers first reported a position in NVNO in Q4 2021 and held it in 6 quarters. The position peaked at $533K in Q4 2021. 17 funds tracked by Wall St. Rank hold NVNO as of Q1 2026.

  • Two Sigma Advisers reported no remaining enVVeno Medical position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 400 enVVeno Medical shares in Q1 2026, an estimated $4.49K.
  • Two Sigma Advisers first reported a position in enVVeno Medical in Q4 2021 and held it in 6 quarters.
  • Two Sigma Advisers's enVVeno Medical position peaked at $533K in Q4 2021.
  • 17 funds tracked by Wall St. Rank held enVVeno Medical as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.